These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

579 related items for PubMed ID: 26577268

  • 1. Treatment of IgA nephropathy.
    Pozzi C.
    J Nephrol; 2016 Feb; 29(1):21-5. PubMed ID: 26577268
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 3. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
    Li X, Liu Y, Lv J, Shi S, Liu L, Chen Y, Zhang H.
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
    [Abstract] [Full Text] [Related]

  • 4. Predictors of Progression in IgA Nephropathy in Childhood.
    Mizerska-Wasiak M, Małdyk J, Turczyn A, Cichoń-Kawa K, Rybi-Szumińska A, Wasilewska A, Bieniaś B, Zajączkowska M, Miklaszewska M, Pietrzyk J, Demkow U, Roszkowska-Blaim M, Pańczyk-Tomaszewska M.
    Adv Exp Med Biol; 2017 Mar; 955():65-73. PubMed ID: 27718216
    [Abstract] [Full Text] [Related]

  • 5. Treatment of IgA nephropathy with renal insufficiency.
    Pozzi C, Sarcina C, Ferrario F.
    J Nephrol; 2016 Aug; 29(4):551-8. PubMed ID: 26743078
    [Abstract] [Full Text] [Related]

  • 6. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G, Liu D, Margetts P, Liu L, Zhao Z, Liu Z, Tang L, Fang Y, Li H, Guo Y, Chen F, Liu F.
    Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
    [Abstract] [Full Text] [Related]

  • 7. Treatment of severe Henoch-Schönlein and immunoglobulin A nephritis. A single center experience.
    Edström Halling S, Söderberg MP, Berg UB.
    Pediatr Nephrol; 2009 Jan; 24(1):91-7. PubMed ID: 18931859
    [Abstract] [Full Text] [Related]

  • 8. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
    Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S.
    Nephrol Dial Transplant; 2009 Jan; 24(1):156-60. PubMed ID: 18685141
    [Abstract] [Full Text] [Related]

  • 9. Prognostic factors and therapy assessment of IgA nephropathy: report from a single unit in iran.
    Soleymanian T, Najafi I, Salimi BH, Broomand B.
    Ren Fail; 2011 Jan; 33(6):572-7. PubMed ID: 21663387
    [Abstract] [Full Text] [Related]

  • 10. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study.
    Tang Y, He H, Sun W, Hu P, Chen X, Xu X.
    Mol Med Rep; 2018 Oct; 18(4):4103-4112. PubMed ID: 30132546
    [Abstract] [Full Text] [Related]

  • 11. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
    Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.
    Hypertens Res; 2004 Dec; 27(12):963-70. PubMed ID: 15894837
    [Abstract] [Full Text] [Related]

  • 12. The effects of cytotoxic therapy in progressive IgA nephropathy.
    Shin JH, Lee JE, Park JH, Lim S, Jang HR, Kwon GY, Huh W, Jung SH, Kim YG, Oh HY, Kim DJ.
    Ann Med; 2016 Dec; 48(3):171-81. PubMed ID: 27031662
    [Abstract] [Full Text] [Related]

  • 13. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis.
    Cheng J, Zhang X, Tian J, Li Q, Chen J.
    Int J Clin Pract; 2012 Oct; 66(10):917-23. PubMed ID: 22994326
    [Abstract] [Full Text] [Related]

  • 14. Pro: STOP immunosuppression in IgA nephropathy?
    Pozzi C.
    Nephrol Dial Transplant; 2016 Nov; 31(11):1766-1770. PubMed ID: 27515694
    [Abstract] [Full Text] [Related]

  • 15. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.
    Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J.
    J Am Soc Nephrol; 2018 Jan; 29(1):317-325. PubMed ID: 29042456
    [Abstract] [Full Text] [Related]

  • 16. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.
    Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Nagata M, Tsuchimoto A, Hirakata H, Kitazono T, Tsuruya K.
    Clin Exp Nephrol; 2016 Oct; 20(5):689-698. PubMed ID: 26564155
    [Abstract] [Full Text] [Related]

  • 17. [IgA nephropathy].
    Alamartine E.
    Rev Prat; 2003 Nov 30; 53(18):2023-6. PubMed ID: 15008216
    [Abstract] [Full Text] [Related]

  • 18. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E, Cerezo I, Macias R, Villa J, Martinez C, Cubero J, Martinez R, Ferreira F, García C.
    Transplant Proc; 2011 Nov 30; 43(6):2187-90. PubMed ID: 21839229
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic approach of patients with IgA nephropathy.
    Goumenos DS, Brown CB.
    Ren Fail; 2004 Mar 30; 26(2):171-7. PubMed ID: 15287202
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial.
    Lv J, Zhang H, Chen Y, Li G, Jiang L, Singh AK, Wang H.
    Am J Kidney Dis; 2009 Jan 30; 53(1):26-32. PubMed ID: 18930568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.